- Home
- TXG vs XENE Comparison
TXG vs XENE Comparison
Compare TXG & XENE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TXG | XENE |
|---|---|---|
| Founded | 2012 | 1996 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Laboratory Analytical Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 3.2B |
| IPO Year | 2019 | 2014 |
Fundamental Metrics
Financial Performance| Metric | TXG | XENE |
|---|---|---|
| Price | $21.98 | $44.90 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 14 | 10 |
| Target Price | $16.82 | ★ $53.30 |
| AVG Volume (30 Days) | ★ 2.6M | 681.4K |
| Earning Date | 05-06-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 76.97 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $245,893,000.00 | $311,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $7.32 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 68.06 | N/A |
| 52 Week Low | $6.78 | $26.74 |
| 52 Week High | $23.56 | $46.60 |
Technical Indicators
Market Signals| Indicator | TXG | XENE |
|---|---|---|
| Relative Strength Index (RSI) | 64.85 | 62.94 |
| Support Level | $11.62 | $39.56 |
| Resistance Level | $23.56 | $46.40 |
| Average True Range (ATR) | 1.29 | 1.51 |
| MACD | 0.20 | 0.36 |
| Stochastic Oscillator | 99.89 | 89.08 |
Price Performance
Historical ComparisonAbout TXG 10x Genomics Inc.
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The company's integrated solutions include instruments, consumables, and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. Its product offerings include a Chromium platform comprising microfluidic chips and related consumables, Chromium X series, Visium and Xenium platforms, and others, which are predominantly used for the study of biological components. Geographically, the company derives maximum revenue from the United States and the rest from Americas (excluding the United States), Europe, Middle East and Africa, China, and Asia-Pacific (excluding China).
About XENE Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.